leadf
logo-loader
view4D pharma PLC

4D pharma chief executive hails appointment of new independent director

Dr Katrin Rupalla brings with her "vast experience guiding novel therapies through the clinic"

4D pharma plc -

4D pharma plc (LON:DDDD) said it has appointed a new independent director to help guide the business to the “next stages of global development”.

Dr Katrin Rupalla’s arrival was announced as 4D also said non-executive director David Norwood would be retiring from the board at the end of the month after six years with the drug developer.

Rupalla is currently head of regulatory affairs, medical documentation and R&D quality at Lundbeck, the Danish drug group. She has also held senior positions at Roche, Celgene and Bristol-Myers Squibb.

In a statement, 4D’s chief executive Duncan Peyton said: "We are delighted to be able to attract someone of Katrin's calibre to our board of directors. Her vast experience guiding novel therapies through the clinic will be invaluable as we progress our pipeline of novel Live Biotherapeutics into and through the clinic. 

“With her background so well aligned with 4D's core focus areas of oncology and CNS, Katrin's experience and network across Europe, the US and China will support 4D's growth as we continue to expand our global profile."

Working in the emerging area of the human microbiome (the bacteria that reside mainly in the gut), 4D has developed Live Biotherapeutics — products that contain live organisms such as human commensal bacteria.

Toxicity has always been a major impediment to the success of new drugs.

In developing its Live Biotherapeutics, 4D has isolated bacteria from healthy human donors which are expected to have “highly attractive safety profiles”.

Quick facts: 4D pharma PLC

Price: 98.11 GBX

LSE:DDDD
Market: LSE
Market Cap: £129.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

4D Pharma shares could re-test 2016’s £10 highs if they do this one thing

The 4D Pharma (LON:DDDD) share price could go on to re-test last year’s highs of £10 if they can break above the 200-day moving average, claims Zak Mir. “Really, one would want to see the shares break outside that range in order to determine fresh direction,” Mir explains in the Proactive...

on 13/1/17

2 min read